CONBA康恩贝品牌怎么样 申请店铺

我要投票 CONBA康恩贝在中草药行业中的票数:279 更新时间:2025-04-20
CONBA康恩贝是哪个国家的品牌?「CONBA康恩贝」是 浙江康恩贝制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人胡季强在1993-01-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力CONBA康恩贝品牌出海!通过在本页面挂载CONBA康恩贝品牌的产品链接和联系邮箱,可以提高CONBA康恩贝产品曝光!跨境电商爆单神器,目前只要100元/年哦~

CONBA康恩贝怎么样

浙江康恩贝制药股份有限公司是康恩贝集团有限公司的控股子公司,前身为创建于1969年的“兰溪云山制药厂”,经过三十余年发展,现已成长为一家实施全产业链经营,集药材种植、提取、研发、生产、销售于一体的大型医药上市企业。至2015年底,公司有员工近万名,注册资本167,382万元。公司于2004年4月在上海证券交易所上市,股票代码为600572。

公司注册地为浙江省兰溪市,管理总部设在浙江省杭州市,产业布局涵盖浙江的杭州、金华、兰溪,以及江西、云南、内蒙古、四川、贵州、黑龙江等地。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、江西天施康中药股份有限公司、浙江康恩贝医药销售有限公司、杭州康恩贝制药有限公司、上海康恩贝医药有限公司、浙江康恩贝药品研究开发有限公司、内蒙古康恩贝药业有限公司、贵州拜特制药有限公司、浙江珍诚医药在线股份有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型企业、国家中药五十强企业、浙江省“五个一批”重点骨干企业、浙江省专利示范企业、国家中药现代化科技产业(浙江)基地示范企业、首批国家知识产权优势企业。经过多年来的技术创新与提升,公司在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发,以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面积累了诸多的优势。

公司历来十分重视产品品牌和企业品牌的培育和保护,在泌尿系统及心脑血管系统等多个领域建立了消费者熟知与认可的品牌,“康恩贝”、“前列康”、“珍视明”、“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”、“恤彤”等均在各自领域内独放异彩,相比同类竞争产品展现了较为突出的品牌优势,承载着用户的由衷认可。

近年来,公司以“内生增长+投资并购”双轮驱动为发展策略,积极推进内部资源的整合,完善营销网络建设,扎实推进研发、质量体系及企业文化的提升,坚定布局医药电商业务,各项工作取得了良好的进展与成果。

展望未来,公司将继续秉承“为员工幸福尽全心全力为人类健康献至诚至爱”的企业使命,恪守“诚实守信、依法经营、质量第一、用户至上、保障安全、友好环境、幸福员工、奉献社会”八大治企基石,以现代中药和植物药产业为核心,发展化学制药、生物制药业务,同时通过产业互联网+与创新,向药业产业链上游(药材种植加工)和下游(医疗与健康服务)拓展延伸,努力建立基于互联网和全产业链的大健康产业生态!

Zhejiang Kangenbei Pharmaceutical Co., Ltd. is the holding subsidiary of Kangenbei Group Co., Ltd., formerly known as "Lanxi Yunshan pharmaceutical factory" founded in 1969. After more than 30 years of development, it has grown into a large pharmaceutical listed enterprise that implements the whole industrial chain operation and integrates the cultivation, extraction, research and development, production and sales of medicinal materials. By the end of 2015, the company had nearly 10000 employees with a registered capital of 1673.82 million yuan. The company was listed on Shanghai Stock Exchange in April 2004 with stock code of 600572. The company is registered in Lanxi City, Zhejiang Province, with its management headquarters in Hangzhou City, Zhejiang Province. Its industrial layout covers Hangzhou, Jinhua, Lanxi, Jiangxi, Yunnan, Inner Mongolia, Sichuan, Guizhou, Heilongjiang, etc. The company has Zhejiang kangenbe traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua kangenbe Biological Pharmaceutical Co., Ltd., Yunnan Xitao green Pharmaceutical Co., Ltd., Jiangxi tianshikang traditional Chinese Medicine Co., Ltd., Zhejiang kangenbe Pharmaceutical Sales Co., Ltd., Hangzhou kangenbe Pharmaceutical Co., Ltd., Shanghai kangenbe Pharmaceutical Co., Ltd., Zhejiang kangenbe pharmaceutical research and Development Co., Ltd , Inner Mongolia Kangenbei Pharmaceutical Co., Ltd., Guizhou Beite Pharmaceutical Co., Ltd., Zhejiang Zhencheng pharmaceutical online Co., Ltd. and other large-scale and powerful wholly-owned and holding subsidiaries. The company is a key high-tech enterprise of national torch plan, a national innovative enterprise, a top 50 enterprise of national traditional Chinese medicine, a key backbone enterprise of "five in one batch" in Zhejiang Province, a patent demonstration enterprise in Zhejiang Province, a demonstration enterprise of national modern science and technology industry (Zhejiang) base of traditional Chinese medicine, and the first batch of national intellectual property advantage enterprises. After years of technological innovation and upgrading, the company has accumulated many advantages in the research and development of cardiovascular and cerebrovascular system drugs, urinary system drugs, anti diabetes drugs, respiratory system drugs, digestive system drugs and anti infective drugs, as well as plant extraction and separation and structural transformation, new drug release system applications and many other aspects. The company has always attached great importance to the cultivation and protection of product brands and enterprise brands. It has established brands well known and recognized by consumers in various fields such as urinary system, cardio cerebrovascular system, etc., "Kangenbei", "QianLieKang", "Zhenshiming", "Tianbaoning", "alexin", "Jinkang", "jinaokang", "Xitao", "Tianbaokang", "Tianshi", "Xiangtong" ”All of them are unique in their respective fields. Compared with similar competitive products, they show more prominent brand advantages and bear the sincere recognition of users. In recent years, the company has taken "endogenous growth + investment merger and acquisition" as its development strategy, actively promoted the integration of internal resources, improved the construction of marketing network, solidly promoted the improvement of R & D, quality system and corporate culture, firmly arranged the pharmaceutical e-commerce business, and made good progress and achievements in various works. Looking forward to the future, the company will continue to uphold the corporate mission of "do our best for the well-being of our employees and the best for human health", adhere to the eight corporate cornerstones of "honesty and trustworthiness, operation according to law, quality first, user first, security, environment-friendly, happy employees, and dedication to the society", and develop chemical pharmacy and biopharmaceutical industry with modern Chinese medicine and plant medicine industry as the core Meanwhile, the industry will expand to the upstream of the pharmaceutical industry chain (medicinal plant processing) and downstream (medical and health services) through the Internet plus and innovation, and strive to build a healthy industrial ecosystem based on the Internet and the whole industry chain.

本文链接: https://brand.waitui.com/ac7af194f.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

后视摄像头图像无法显示,克莱斯勒在美召回48494辆汽车

当地时间4月19日,美国国家公路交通安全管理局(NHTSA)文件披露,由于显示模块可能无法显示后视摄像头图像,克莱斯勒将召回部分2023-2025年款阿尔法·罗密欧Tonale托纳利和道奇大黄蜂,共计48494辆。(界面)

22分钟前

一季度北京地区进出口7198.9亿元 汽车产业拉动出口增长

4月19日,据北京海关消息,今年一季度北京地区(含中央在京单位)进出口7198.9亿元。其中,出口1480.9亿元,较去年同期增长2.2%。北京外贸含“新”量进一步提升。一季度,北京地区汽车产业出口128.1亿元,同比增长56%,上拉同期地区出口增速3.2个百分点,拉动作用最强。同期,医药健康产业、绿色低碳产业分别出口31.6亿元、19亿元,同比分别增长5.8%、119.1%。

22分钟前

上海国际集团与宝山区签署战略合作框架协议 支持绿色低碳、新材料、机器人等发展

4月19日,上海国际集团与宝山区签署战略合作框架协议。双方将通过北转型基金提级扩募,重点支持宝山绿色低碳、新材料、机器人及智能制造等主导产业发展,以全链条金融服务赋能科创产业升级,并加强上市平台培育。(财联社)

22分钟前

一季度重庆外贸进出口总值1651.4亿元 同比增长4.1%

4月19日,重庆海关发布消息称,2025年一季度,重庆外贸进出口总值为1651.4亿元(人民币,下同),同比增长4.1%。据重庆海关介绍,2025年一季度,东盟是重庆第一大贸易伙伴,进出口281.4亿元,同比增长10.5%。此外,重庆对拉美、中东、非洲等新兴市场分别同比增长30.9%、9.2%、41.2%,外贸“朋友圈”持续扩大。

22分钟前

改善患者肢体运动功能 “植入式迷走神经刺激系统”临床试验启动

4月19日,国家卫生健康委组织实施“百万减残”工程重点推广项目,我国自主研发的“植入式迷走神经刺激系统”临床试验正式全国启动。该项目有望成为我国卒中后残疾防控的重要手段。迷走神经电刺激作为一种微创手术,可以辅助脑卒中患者康复治疗。数据显示,该技术能够在卒中后康复黄金期6月以后,帮助患者持续重建神经功能,明显改善患侧肢体运动功能。(财联社)

22分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询